Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Cited by (1,051)

Items 401–500 of 1,051

1. Tumor infiltrating lymphocytes in ovarian cancer
   Phillip P. Santoiemma, Daniel J. Powell · 2015 · Cancer Biology & Therapy
2. The future of epigenetic therapy in solid tumours—lessons from the past
   Nilofer Saba Azad, Cynthia A. Zahnow, Charles M. Rudin, Stephen B. Baylin · 2013 · Nature Reviews Clinical Oncology
3. PD-1 and its ligands are important immune checkpoints in cancer
   Yinan Dong, Qian Sun, Xinwei Zhang · 2016 · Oncotarget
4. Immune evasion through mitochondrial transfer in the tumour microenvironment
   Ikeda, Hideki, Kawase, Katsushige, Nishi, Tatsuya, Watanabe, Tomofumi, Takenaga, Keizo, Inozume, Takashi, Ishino, Takamasa, Aki, Sho, Lin, Jason, Kawashima, Shusuke et al. · 2025 · Nature
5. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
   George K. Philips, Michael B. Atkins · 2014 · International Immunology
6. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
   John R. Webb, Katy Milne, David R. Kroeger, Brad H. Nelson · 2016 · Gynecologic Oncology
7. Microenvironmental Determinants of Pancreatic Cancer
   Elisabeth Heßmann, S Buchholz, İhsan Ekin Demir, Shiv K. Singh, Thomas Mathias Gress, Volker Ellenrieder, Albrecht Neeße · 2020 · Physiological Reviews
8. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
   Gagan K. Gupta, Amber L. Collier, Dasom Caroline Lee, Richard A. Hoefer, Vasilena P. Zheleva, Lauren L. Siewertsz van Reesema, Angela M. Tang-Tan, Mary L. Guye, David Z. Chang, Janet S. Winston et al. · 2020 · Cancers
9. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy
   Jiang, Qin, Wang, Kuang, Zhang, Xingyu, Ouyang, Boshu, Liu, Haixia, Pang, Zhiqing, Yang, Wuli · 2020 · Small
10. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer
    Lin, Anqi, Zhang, Jian, Luo, Peng · 2020 · Frontiers in Immunology
11. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
    Maute, Roy L., Gordon, Sydney R., Mayer, Aaron T., McCracken, Melissa N., Natarajan, Arutselvan, Ring, Nan Guo, Kimura, Richard, Tsai, Jonathan M., Manglik, Aashish, Kruse, Andrew C. et al. · 2015 · Proceedings of the National Academy of Sciences
12. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
    Ingunn M. Stromnes, J. Scott Brockenbrough, Kamel Izeradjene, Markus A. Carlson, Carlos Mario Cuevas, Randi M. Simmons, Philip D. Greenberg, Sunil R. Hingorani · 2014 · Gut
13. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
    Williams, Patrick, Basu, Sreyashi, Garcia‐Manero, Guillermo, Hourigan, Christopher S., Oetjen, Karolyn A., Cortes, Jorge E., Ravandi, Farhad, Jabbour, Elias J., Al‐Hamal, Zainab, Konopleva, Marina et al. · 2019 · Cancer
14. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer
    Mirji, Gauri, Worth, Alison, Bhat, Sajad Ahmad, El Sayed, Mohamed, Kannan, Toshitha, Goldman, Aaron R., Tang, Hsin-Yao, Liu, Qin, Auslander, Noam, Dang, Chi V. et al. · 2022 · Science Immunology
15. HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
    Huanbin Wang, Han Yao, Chushu Li, Hubing Shi, Jiang Lan, Zhaoli Li, Yao Zhang, Lunxi Liang, Jing‐Yuan Fang, Jie Xu · 2018 · Nature Chemical Biology
16. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
    Lijie Zhai, Stefani Spranger, David C. Binder, Galina Gritsina, Kristen L. Lauing, Francis Joseph Giles, Derek Alan Wainwright · 2015 · Clinical Cancer Research
17. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
    Xun Wang, Lingyun Yang, Feng Huang, Qiuyang Zhang, Sen Liu, Lin Ma, Zongbing You · 2017 · Immunology Letters
18. Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy
    Keman Cheng, Yanping Ding, Ying Zhao, Shefang Ye, Xiao Zhao, Yinlong Zhang, Tianjiao Ji, Huanhuan Wu, Bin Wang, Gregory Jon Anderson et al. · 2018 · Nano Letters
19. Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth
    Sarah Davidson, Mirjana Efremova, Angela Riedel, Bidesh Mahata, Jhuma Pramanik, Jani Huuhtanen, Gozde Kar, Roser Vento‐Tormo, Tzachi Hagai, Xi Xian Chen et al. · 2020 · Cell Reports
20. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
    Faje, Alexander · 2016 · Pituitary
21. Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment
    Kato, Takuya, Noma, Kazuhiro, Ohara, Toshiaki, Kashima, Hajime, Katsura, Yuki, Sato, Hiroaki, Komoto, Satoshi, Katsube, Ryoichi, Ninomiya, Takayuki, Tazawa, Hiroshi et al. · 2018 · Clinical Cancer Research
22. CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
    Qunrui Ye, De-Gang Song, Mathilde Poussin, Tori N. Yamamoto, Andrew J. Best, Chunsheng Li, George Coukos, Daniel J. Powell · 2013 · Clinical Cancer Research
23. Role of Immune Cells and Immune-Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma
    Lei Zheng, Jing Xue, Elizabeth M. Jaffee, Aida Habtezion · 2013 · Gastroenterology
24. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
    David J. Messenheimer, Shawn M. Jensen, Michael E. Afentoulis, Keith W. Wegmann, Zipei Feng, David J. Friedman, Michael J. Gough, Walter John Urba, Bernard A. Fox · 2017 · Clinical Cancer Research
25. Refining the treatment of NSCLC according to histological and molecular subtypes
    Anish Thomas, Stephen V. Liu, Deepa Suresh Subramaniam, Giuseppe Giaccone · 2015 · Nature Reviews Clinical Oncology
26. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
    Chad Z. Tang, Xiaohong Wang, Hendrick Soh, Steven Neema Seyedin, María Angélica Cortez, Sunil Krishnan, Erminia Massarelli, David S. Hong, Aung Naing, Adi K. Diab et al. · 2014 · Cancer Immunology Research
27. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
    Delphine Rossille A, M Gressier, Diane Damotte, Delphine Maucort‐Boulch, Céline Pangault, G. Sémana, Steven Le Gouill, Corinne Haïoun, Karin Tarte, T Lamy et al. · 2014 · Leukemia
28. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
    Inge C. van Gool, Florine A. Eggink, Luke Freeman-Mills, Ellen Stelloo, Emanuele Marchi, Marco de Bruyn, Claire Palles, Remi A. Nout, Cor Doede de Kroon, Elisabeth M. Osse et al. · 2015 · Clinical Cancer Research
29. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
    Jiang, Yuanyuan, Zhan, Hanxiang · 2020 · Cancer Letters
30. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
    Heinz Philipp Laubli, Cathrin Balmelli, Matthias Bossard, Otmar Pfister, Kathrin Glatz, Alfred Zippelius · 2015 · Journal for ImmunoTherapy of Cancer
31. The changing immune system in sepsis
    Jonathan S. Boomer, Jonathan M. Green, Richard S. Hotchkiss · 2013 · Virulence
32. PD-1/PD-L1 and immunotherapy for pancreatic cancer
    Mengyu Feng, Guangbing Xiong, Zhe Cao, Gang Yang, Suli Zheng, Xujun Song, Lei You, Lianfang Zheng, Taiping Zhang, Yupei Zhao · 2017 · Cancer Letters
33. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
    Bellucci, Roberto, Martin, Allison, Bommarito, Davide, Wang, Kathy, Hansen, Steen H, Freeman, Gordon J, Ritz, Jerome · 2015 · OncoImmunology
34. Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review
    Shreya Thakkar, Dilip Sharma, Kiran Kalia, Rakesh Kumar Tekade · 2019 · Acta Biomaterialia
35. Exhaustion-associated regulatory regions in CD8 + tumor-infiltrating T cells
    Giuliana P. Mognol, Roberto Spreafico, Victor Wong, James P Scott-Browne, Susan Togher, Alexander Hoffmann, Patrick G. Hogan, Anjana Rao, Sara Trifari · 2017 · Proceedings of the National Academy of Sciences
36. CD8+ T cell exhaustion
    Makoto Kurachi · 2019 · Seminars in Immunopathology
37. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
    Asma Beldi‐Ferchiou, Marion Lambert, Stéphanie Dogniaux, Frédéric Vely, Éric Vivier, Daniel Olive, Stéphanie Dupuy, Franck Levasseur, David Zucman, Célèste Lebbé et al. · 2016 · Oncotarget
38. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
    Shunli Peng, Rong Wang, Xiaojuan Zhang, Yueyun Ma, Longhui Zhong, Ke Li, Akihiro Nishiyama, Sachiko Arai, Seiji Yano, Wei Wang · 2019 · Molecular Cancer
39. Emerging biomarkers in head and neck cancer in the era of genomics
    Hyunseok Kang, Ana P. Kiess, Christine H. Chung · 2014 · Nature Reviews Clinical Oncology
40. Combining Epigenetic and Immunotherapy to Combat Cancer
    Katherine Bakshian Chiappinelli, Cynthia A. Zahnow, Nita Ahuja, Stephen B. Baylin · 2016 · Cancer Research
41. Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
    Riera-Domingo, Carla, Audigé, Annette, Granja, Sara, Cheng, Wan-Chen, Ho, Ping-Chih, Baltazar, Fátima, Stockmann, Christian, Mazzone, Massimiliano · 2020 · Physiological Reviews
42. Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
    Sine Reker Hadrup, Marco Donia, Per thor Straten · 2012 · Cancer Microenvironment
43. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
    Ruea-Yea Huang, Cheryl Eppolito, Shashikant Lele, Protul A. Shrikant, Junko Matsuzaki, Kunle O. Odunsi · 2015 · Oncotarget
44. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
    Li Shi, Shaohua Chen, Lijian Yang, Yangqiu Li · 2013 · Journal of Hematology & Oncology
45. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
    Lindsay Angus, Marcel Smid, Saskia M. Wilting, Job van Riet, Arne van Hoeck, Luan Nguyen, Serena Nik‐Zainal, Tessa Gerjanne Steenbruggen, Vivianne C. G. Tjan‐Heijnen, Mariëtte Labots et al. · 2019 · Nature Genetics
46. Microbiota in pancreatic health and disease: the next frontier in microbiome research
    Ryan Michael Thomas, Christian Jobin · 2019 · Nature Reviews Gastroenterology & Hepatology
47. Immunotherapy and tumor microenvironment
    Haidong Tang, Jian Qiao, Yang‐Xin Fu · 2015 · Cancer Letters
48. Stromal Cells in the Tumor Microenvironment
    Alice E. Denton, Edward W. Roberts, Douglas T. Fearon · 2018 · Advances in experimental medicine and biology
49. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis
    Katherine C. Chang, Catherine Svabek, Cristina Vazquez Guillamet, Bryan Sato, David P Rasche, Strother Wilson, Paul B. Robbins, Nancy D. Ulbrandt, JoAnn Suzich, Jonathan M. Green et al. · 2014 · Critical Care
50. Antagonists of PD-1 and PD-L1 in Cancer Treatment
    Evan J. Lipson, Patrick M. Forde, Hans-Joerg Hammers, Leisha A. Emens, Janis Marie Taube, Suzanne Louise Topalian · 2015 · Seminars in Oncology
51. Delivering safer immunotherapies for cancer
    Lauren E. Milling, Yuan Zhang, Darrell J. Irvine · 2017 · Advanced Drug Delivery Reviews
52. Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
    Nicholas A. Ullman, Paul R. Burchard, Richard Francis Dunne, David C. Linehan · 2022 · Journal of Clinical Oncology
53. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
    Anish Thomas, Arun Rajan, Arlene W. Berman, Yusuke Tomita, Christina E. Brzezniak, Min-Jung Lee, Sunmin Lee, Alexander Lee Ling, Aaron John Spittler, Corey Allan Carter et al. · 2015 · The Lancet Oncology
54. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
    Shelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, Karen Byth, Benjamin Y. Kong, Shaun Chou, Matteo Salvatore Carlino, Richard F. Kefford, Pablo Fernández‐Peñas · 2016 · Journal of the American Academy of Dermatology
55. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer
    Fernando Concha‐Benavente, Raghvendra Mohan Srivastava, Sumita Trivedi, Yu L. Lei, Uma R. Chandran, Raja R. Seethala, Gordon James Freeman, Robert Louis Ferris · 2015 · Cancer Research
56. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
    Shu Su, Bian Hu, Jie Shao, Bin Shen, Juan Du, Yinan Du, Jiankui Zhou, Lixia Yu, Lianru Zhang, Fangjun Chen et al. · 2016 · Scientific Reports
57. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
    H. Raza Ali, Silvia-Elena Glont, Fiona M. Blows, Elena Provenzano, Sarah‐Jane Dawson, B. Liu, Louise Hiller, Janet Dunn, C. J. Poole, Sarah Jane Bowden et al. · 2015 · Annals of Oncology
58. Precision diagnosis and treatment of liver cancer in China
    Jing Fu, Hongyang Wang · 2017 · Cancer Letters
59. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
    Neda Yaghoubi, Arash Soltani, Kiarash Ghazvini, Seyed Mahdi Hassanian, Seyed Isaac Hashemy · 2018 · Biomedicine & Pharmacotherapy
60. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
    David D. W. Twa, Fong Chun Chan, Susana Ben‐Neriah, Bruce W. Woolcock, Anja Mottok, King L. Tan, Graham W. Slack, Jay Gunawardana, Raymond S. Lim, Andrew McPherson et al. · 2014 · Blood
61. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
    Daniel E. Speiser, Daniel T. Utzschneider, Susanne G. Oberle, Christian Münz, Pedro J. Romero, Dietmar Zehn · 2014 · Nature reviews. Immunology
62. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
    Shuhang Wang, Yongping Song, Delong Liu · 2016 · Cancer Letters
63. Chemotherapy induces enrichment of CD47 ⁺ /CD73 ⁺ /PDL1 ⁺ immune evasive triple-negative breast cancer cells
    Samanta, Debangshu, Park, Youngrok, Ni, Xuhao, Li, Huili, Zahnow, Cynthia A., Gabrielson, Edward, Pan, Fan, Semenza, Gregg L. · 2018 · Proceedings of the National Academy of Sciences
64. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade
    Natalija Budimir, Graham D. Thomas, Joseph S. Dolina, Shahram Salek‐Ardakani · 2021 · Cancer Immunology Research
65. Temozolomide for immunomodulation in the treatment of glioblastoma
    Aida Karachi, Farhad Dastmalchi, Duane A. Mitchell, Maryam Rahman · 2018 · Neuro-Oncology
66. Cancer and the Immune System: Basic Concepts and Targets for Intervention
    Drew M. Pardoll · 2015 · Seminars in Oncology
67. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
    Erin E. West, Hyun‐Tak Jin, Ata Ur Rasheed, Pablo Penaloza‐MacMaster, Sang‐Jun Ha, Wendy G. Tan, Ben Youngblood, Gordon James Freeman, Kendall A. Smith, Rafi Ahmed · 2013 · Journal of Clinical Investigation
68. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
    Sander Kelderman, Bianca Heemskerk, Harm van Tinteren, Rob R. H. van den Brom, Geke A.P. Hospers, Alfons J.M. van den Eertwegh, Ellen Kapiteijn, Jan Willem B. de Groot, Patricia M.M.B. Soetekouw, Rob L. H. Jansen et al. · 2014 · Cancer Immunology Immunotherapy
69. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
    Paula D. Bos, George Plitas, Dipayan Rudra, Sue Y. Lee, Alexander Yu Rudensky · 2013 · The Journal of Experimental Medicine
70. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer
    Byrne, Katelyn T., Vonderheide, Robert H. · 2016 · Cell Reports
71. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
    Bert H. O’Neil, John M. Wallmark, David Lorente, Elena Élez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina Anne Piha-Paul, Mark N. Stein, Albiruni R. Abdul Razak et al. · 2017 · PLoS ONE
72. Radiopharmaceuticals and their applications in medicine
    Siqi Zhang, Xingkai Wang, Xin Gao, Xueyao Chen, Linger Li, Guoqing Li, Can Liu, Yuan Miao, Rui Wang, Kuan Hu · 2025 · Signal Transduction and Targeted Therapy
73. The intracellular signalosome of PD-L1 in cancer cells
    David Escors, María Gato, Miren Zuazo, Hugo Arasanz, María Jesús García-Granda, Ruth Vera, Grazyna T. Kochan · 2018 · Signal Transduction and Targeted Therapy
74. B7-H3/CD276: An Emerging Cancer Immunotherapy
    Wu-Tong Zhou, Weilin Jin · 2021 · Frontiers in Immunology
75. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
    Wendy A. Cooper, Thang Tran, Ricardo E. Vilain, Jason Madore, Christina I. Selinger, Maija R.J. Kohonen‐Corish, Po Yee Yip, Bing Yu, Sandra A. O’Toole, Brian C. McCaughan et al. · 2015 · Lung Cancer
76. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
    Chalabi, M., Cardona, A., Nagarkar, D.R., Dhawahir Scala, A., Gandara, D.R., Rittmeyer, A., Albert, M.L., Powles, T., Kok, M., Herrera, F.G. · 2020 · Annals of Oncology
77. Immunotherapy, Inflammation and Colorectal Cancer
    Charles Robert Lichtenstern, Rachael Katie Ngu, Shabnam Shalapour, Michael Karin · 2020 · Cells
78. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
    Gregory Lawrence Beatty, Rafael Winograd, Rebecca A. Evans, Kristen B. Long, Santiago L. Luque, Jae Woo Lee, Cynthia J. Clendenin, Whitney Lynn Gladney, Dawson M. Knoblock, Patrick D. Guirnalda et al. · 2015 · Gastroenterology
79. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
    Meredith L. Stone, Katherine Bakshian Chiappinelli, Huili Li, Lauren M. Murphy, Meghan E. Travers, Michael J. Topper, Dimitrios Mathios, Michael K. Lim, Ie‐Ming Shih, Tian‐Li Wang et al. · 2017 · Proceedings of the National Academy of Sciences
80. The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance
    Fearon, Douglas T. · 2014 · Cancer Immunology Research
81. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer
    Daniel Cui Zhou, Reyka G. Jayasinghe, Siqi Chen, John M. Herndon, Michael D. Iglesia, Pooja Navale, Michael C. Wendl, Wagma Caravan, Kazuhito Sato, Erik P. Storrs et al. · 2022 · Nature Genetics
82. Molecularly targeted cancer therapy: some lessons from the past decade
    Min Huang, Aijun Shen, Jian Ding, Meiyu Geng · 2013 · Trends in Pharmacological Sciences
83. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
    Ashton Anthony Connor, Robert Edward Denroche, Gun Ho Jang, Lee E. Timms, Sangeetha N. Kalimuthu, Iris Selander, Treasa A. McPherson, Gavin W. Wilson, Michelle Chan‐Seng‐Yue, Ivan Borozan et al. · 2016 · JAMA Oncology
84. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
    Zijun Yidan Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young · 2017 · Frontiers in Immunology
85. PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy
    Xudong Zhang, Chao Wang, Jinqiang Wang, Quanyin Hu, Benjamin Langworthy, Yanqi Ye, Wujin Sun, Jing Lin, Tianfu Wang, Jason P. Fine et al. · 2018 · Advanced Materials
86. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
    Matthew W. Rosenbaum, Jacob R. Bledsoe, Vicente Morales‐Oyarvide, Tiffany G. Huynh, Mari A. Mino-Kenudson · 2016 · Modern Pathology
87. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells
    Abdullah Alsuliman, Dilek Çolak, Olfat Al‐Harazi, Hanaa Fitwi, Asma M. Tulbah, Taher Al‐Tweigeri, Monther M Al-Alwan, Hazem Ghebeh · 2015 · Molecular Cancer
88. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
    Ju‐Yeun Lee, Hyun Tae Lee, Woori Shin, Jongseok Chae, Jaemo Choi, Sung Hyun Kim, Heejin Lim, Tae Won Heo, Kyeong Young Park, Yeon Ji Lee et al. · 2016 · Nature Communications
89. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
    Yoh Zen, Matthew M. Yeh · 2018 · Modern Pathology
90. Macrophages, Inflammation, and Lung Cancer
    Emma M. Conway, Larissa A. Pikor, Sonia H.Y. Kung, Melisa J. Hamilton, Stephen C. Lam, Wan L. Lam, Kevin L. Bennewith · 2015 · American Journal of Respiratory and Critical Care Medicine
91. The immune system and response to HER2-targeted treatment in breast cancer
    Giampaolo Bianchini, Luca Gianni · 2014 · The Lancet Oncology
92. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response
    Yu Wang, Yiyi Liang, Haiyan Xu, Xiao Zhang, Tiebo Mao, Jiujie Cui, Jiayu Yao, Yongchao Wang, Feng Jiao, Xiuying Xiao et al. · 2021 · Cell Discovery
93. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
    Ching‐Yao Yang, Mong‐Wei Lin, Yih‐Leong Chang, Chen‐Tu Wu, Pan‐Chyr Yang · 2014 · European Journal of Cancer
94. Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
    Dallas B. Flies, Xue Na Han, Tomoe Higuchi, Linghua Zheng, Jingwei Sun, Jessica Jane Ye, Lieping Chen · 2014 · Journal of Clinical Investigation
95. Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis
    Katherine C. Chang, Carey‐Ann D. Burnham, Stephanie M. Compton, David P Rasche, Richard J. Mazuski, Jacquelyn SMcDonough, Jacqueline Unsinger, Alan J. Korman, Jonathan M. Green, Richard S. Hotchkiss · 2013 · Critical Care
96. CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
    Christine E. Engeland, Christian Grossardt, Rūta Veinalde, Sascha Bossow, Diana Lutz, Johanna K. Kaufmann, Ivan Shevchenko, Viktor Umansky, Dirk M. Nettelbeck, Wilko Weichert et al. · 2014 · Molecular Therapy
97. Nanomaterials for cancer immunotherapy
    Wantong Song, Sara Musetti, Leaf Huang · 2017 · Biomaterials
98. Eosinophils: The unsung heroes in cancer?
    Gilda Varricchi, Maria Rosaria Galdiero, Stefania Loffredo, Valeria Lucarini, Giancarlo Marone, Fabrizio Mattei, Gianni Marone, Giovanna Schiavoni · 2017 · OncoImmunology
99. Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
    Andréa Varga, Sarina Anne Piha-Paul, Patrick Alexander Ott, Janice M. Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane I. Ruman, Daniela Elena Matei · 2018 · Gynecologic Oncology
100. Pembrolizumab for the treatment of non-small cell lung cancer
     Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn · 2016 · Expert Opinion on Biological Therapy